Skip to main content
Premium Trial:

Request an Annual Quote

Integrated Genomics Licenses Gene Sequencing Technologies to Genencor

NEW YORK, Sept. 26 – Integrated Genomics of Chicago has licensed three of its microbial genome sequencing technologies to Genencor, the companies announced Tuesday.

Under the terms of the deal Genencor will have a license to use Integrated Genomics’ genome sequence data for Aspergillus niger , the ERGO bioinformatics tools, and Genome Explorer, which allows scientists to analyze regulatory pathways.

Genencor of Palo Alto, Calif., said it would apply these technologies to study fungal cell factories and to look for commercial applications of novel biological products.

"Over the years, we have invested significantly in our functional genomics platform and we believe that the A. niger  genome sequence specifically will accelerate the pace of enzyme discovery and production," Michael Arbige, senior vice president of technology for Genencor, said in a statement. 

“The sequence data and the blueprint of metabolism will lead us to design cell factories from a whole-system perspective for both our bioproducts and health care projects,” he said.

A. niger  is a fungus that can convert simple molecules into complex biochemicals. 

Integrated Genomics has also used its ERGO bioinformatics system to organize A. niger ’s genes and their functions into metabolic networks.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.